샘플 요청 목록

 카트 문의
시장보고서
상품코드
1533901

세계의 기생충 질환 치료제 시장

Parasitic Diseases Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 279 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

기생충 질환 치료제 시장은 2030년까지 22억 달러에 달할 전망입니다.

2023년에 17억 달러로 추정된 기생충 질환 치료제 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 3.3%로 성장하여, 2030년에는 22억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 구충제는 복합 연간 성장률(CAGR) 3.5%로 성장을 지속하여, 분석 기간 종료 시 11억 달러에 달할 것으로 예측됩니다. 항원충제 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 2.8%로 추정됩니다.

미국 시장은 4억 7,310만 달러로 추정되며, 중국은 복합 연간 성장률(CAGR) 6.4%로 성장 예측됩니다.

미국 기생충 질환 치료제 시장은 2023년 4억 7,310만 달러로 추정됩니다. 세계의 2위 경제대국인 중국은 2030년까지 4억 4,950만 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR)은 6.4%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR)은 각각 1.0%와 2.5%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 1.7%로 성장할 것으로 예측됩니다.

세계의 기생충 질환 치료제 시장 : 주요 동향과 촉진요인 정리

원충, 기생충, 외부 기생충 등 다양한 생물에 의해 야기되는 기생충병은 특히 열대,아열대 지역에 있어서, 세계적으로 공중 위생상의 중대한 과제를 가져오고 있습니다. 말라리아, 리슈마니아증, 주혈흡충증, 림프계 필라리아증 등을 비롯한 이러한 질환은 특히 소아와 면역 결핍증 사이에서 심각한 이환율과 사망률을 유발합니다. 기생충증의 치료에는 숙주의 체내에서 기생충을 제거하고, 증상을 완화하고, 감염을 예방하는 것을 목표로 한 다양한 치료법이 있습니다. 종래의 치료에서는 말라리아에는 클로로킨, 연충 감염증에는 알벤다졸 등의 항기생충약이 사용되어 수십 년에 걸쳐 치료의 중심이 되어 왔습니다. 그러나 기생충의 약물 내성 균주의 출현은 이러한 질병과 싸우기 위해보다 효과적인 새로운 치료제의 개발을 필요로합니다.

기생충병 치료제 분야의 최근 동향은 신약 발견, 백신 개발 및 병용 요법에 중점을 둔 혁신적인 연구 개발에 의해 견인되었습니다. 기생충의 생태를 보다 깊이 이해하고 새로운 창약 표적을 발견하기 위해 연구자들은 고처리량 스크리닝 기술을 활용하여 신약 후보를 확인하고 유전체학와 단백질체학의 진보를 활용하고 있습니다. 말라리아 백신 RTS, S/AS01과 같은 기생충병에 대한 백신의 개발은 감염 예방과 질병 부담의 경감에 있어서 중요한 돌파구가 됩니다. 또한 치료 효과를 높이고 약물 내성의 발현을 늦추기 위해 작용기전이 다른 여러 약물을 사용하는 병용 요법이 점점 활용되고 있습니다. 기생충의 복잡한 수명주기와 다양한 조건에서 적응하고 생존하는 능력을 고려할 때 이러한 다면적 접근법은 기생충 질환 관리에 매우 중요합니다.

기생충 질환 치료제 시장의 개척은 세계의 여행, 기후 변화, 신흥국의 불충분한 위생 환경 등에 의한 기생충 감염의 유행 증가 등 여러 요인에 의해 추진되고 있습니다. 진단 도구의 기술적 진보는 기생충 질환의 조기 발견과 정확한 진단을 향상 시켰고 적시에 효과적인 치료를 용이하게했습니다. 소비자 행동, 특히 질병의 만연률이 높은 지역에서는 사용하기 쉽고 저렴한 치료에 대한 수요가 높아지고 있습니다. 또한 세계의 보건기구(WHO) 및 빌 앤 멜린다 게이츠 재단(Bill & Melinda Gates Foundation)과 같은 조직의 세계의 건강 이니셔티브와 자금 지원이이 분야의 연구 개발에 큰 지원이되었습니다. 새로운 항기생충제 및 백신에 대한 규제 우대 조치 및 신속한 승인도 시장 성장에 기여합니다. 제약기업이 혁신적인 치료법에 대한 투자를 계속하고 신흥 시장 진출을 확대하는 가운데 기생충 질환 치료제시장은 성장이 예상되고 감염자의 건강상태 개선과 삶의 질 향상 기대됩니다.

조사 대상 기업 예(전 42건)

  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Cipla Ltd
  • GSK Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Reese Pharmaceutical Company
  • Sanaria Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Victor Medical Company
  • Zydus Pharmaceuticals(USA) Inc.
  • ;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.08.22

Global Parasitic Diseases Therapeutics Market to Reach US$2.2 Billion by 2030

The global market for Parasitic Diseases Therapeutics estimated at US$1.7 Billion in the year 2023, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Anthelmintics Drugs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Antiprotozoals Drugs segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$473.1 Million While China is Forecast to Grow at 6.4% CAGR

The Parasitic Diseases Therapeutics market in the U.S. is estimated at US$473.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$449.5 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Parasitic Diseases Therapeutics Market - Key Trends and Drivers Summarized

Parasitic diseases, caused by various organisms such as protozoa, helminths, and ectoparasites, continue to pose significant public health challenges worldwide, particularly in tropical and subtropical regions. These diseases, including malaria, leishmaniasis, schistosomiasis, and lymphatic filariasis, often result in severe morbidity and mortality, particularly among children and immunocompromised individuals. Therapeutics for parasitic diseases involve a range of treatments designed to eliminate the parasites from the host body, alleviate symptoms, and prevent transmission. Traditional treatments have included antiparasitic drugs such as chloroquine for malaria and albendazole for helminth infections, which have been the mainstay of treatment for decades. However, the emergence of drug-resistant strains of parasites has necessitated the development of new and more effective therapeutics to combat these diseases.

Recent advancements in the field of parasitic disease therapeutics have been driven by innovative research and development efforts focusing on novel drug discovery, vaccine development, and combination therapies. Researchers are employing high-throughput screening techniques to identify new drug candidates, leveraging advances in genomics and proteomics to understand parasite biology better and discover new drug targets. The development of vaccines against parasitic diseases, such as the RTS,S/AS01 malaria vaccine, represents a significant breakthrough in preventing infection and reducing disease burden. Additionally, combination therapies, which use multiple drugs with different mechanisms of action, are being increasingly utilized to enhance treatment efficacy and delay the onset of drug resistance. This multifaceted approach is crucial in managing parasitic diseases, given the complex life cycles of parasites and their ability to adapt and survive under various conditions.

The growth in the parasitic diseases therapeutics market is driven by several factors, including the increasing prevalence of parasitic infections due to global travel, climate change, and inadequate sanitation in developing regions. Technological advancements in diagnostic tools have improved the early detection and accurate diagnosis of parasitic diseases, facilitating timely and effective treatment. Consumer behavior, particularly in regions with high disease prevalence, shows a growing demand for accessible and affordable treatments. Additionally, global health initiatives and funding from organizations such as the World Health Organization (WHO) and the Bill & Melinda Gates Foundation have provided substantial support for research and development in this field. Regulatory incentives and fast-track approvals for new antiparasitic drugs and vaccines also contribute to market growth. As pharmaceutical companies continue to invest in innovative treatments and expand their reach into emerging markets, the parasitic diseases therapeutics market is expected to grow, offering improved health outcomes and enhanced quality of life for affected populations.

Select Competitors (Total 42 Featured) -

  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Cipla Ltd
  • GSK Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Reese Pharmaceutical Company
  • Sanaria Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals USA, Inc.
  • Victor Medical Company
  • Zydus Pharmaceuticals (USA) Inc.
  • ;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Parasitic Diseases Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Burden of Parasitic Diseases Drives Urgent Need for Effective Therapeutics
    • Breakthroughs in Molecular Biology and Parasitology Propel Drug Development
    • Expansion of Global Health Initiatives to Combat Malaria, Chagas Disease, and Others to Benefit Growth
    • Impact of Climate Change on Parasitic Disease Spread and Epidemiology
    • Governmental Funding and Policy Support for Neglected Tropical Diseases, Remain Crucial for New Drug Development
    • Development of Vaccines as a Preventative Strategy Against Parasitic Infections
    • Rising Travel and Migration Patterns Influence Disease Transmission Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Parasitic Diseases Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Parasitic Diseases Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anthelmintics Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anthelmintics Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Anthelmintics Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antiprotozoals Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antiprotozoals Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antiprotozoals Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channel Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channel Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channel Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Parasitic Diseases Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Parasitic Diseases Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Parasitic Diseases Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Parasitic Diseases Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Parasitic Diseases Therapeutics by Drug Type - Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Parasitic Diseases Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Anthelmintics Drugs, Antiprotozoals Drugs and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Parasitic Diseases Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Parasitic Diseases Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channel Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제